HIV Diagnostic Tests. HIV Testing Algorithm at SydPath (National Reference Laboratory)

Similar documents
Frequently Asked Questions: IS RT-Q-PCR Testing

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

17/05/2011. Preventing Donor Derived Infections Through Virology Screening Reducing Risk and Increasing Organ Availability OUTLINE OUTLINE

Lyme Disease Surveillance in North Carolina

Genotyping of Human Papillomavirus

Chapter 6: Impact Indicators

ALCAT FREQUENTLY ASKED QUESTIONS

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

US Public Health Service Clinical Practice Guidelines for PrEP

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

PROTOCOL 1850 Millrace Drive, Suite 3A Eugene, Oregon

INFERTILITY DIAGNOSIS

Tick fever is a cattle disease caused by any one of the following blood parasites:

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

How to become an AME Online

Specifically, on page 12 of the current evicore draft, we find the statement:

Referral Criteria: Inflammation of the Spine Feb

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

Belgian Volition SA - a VolitionRx Company- Technological company presentation BIOWIN DAY 2014

Recommendations for Risk Management at Swine Exhibitions and for Show Pigs August 2012

Key Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)

Widening of funding restrictions for rituximab and eltrombopag


ACRIN 6666 Screening Breast US Follow-up Assessment Form

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.

Medical Student Immunization Requirements

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information

Waterloo Wellington Rehabilitative Care System Integrated Care Pathway for STROKE Stream of Care HYPERACUTE URGENT TIA and SECONDARY STROKE PREVENTION

Childhood Immunization Status (NQF 0038)

PROTOCOL. SOD2 Protein Quantity Microplate Assay Kit. MS746 Rev.0 DESCRIPTION INTRODUCTION

MGPR Training Courses Guide

Trust Guideline for Urgent Brain Imaging and Management of Suspected Subarachnoid Haemorrhage

2017 CMS Web Interface

Osteoporosis Fast Facts

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers

Response to. type 2 vaccine-derived polioviruses. prior to global topv withdrawal. Interim Guidelines

Cross-Platform Comparison of IL-6 Immunoassays. Maribeth Raines, PhD. Vice President of Laboratory Services. May 17, 2016 Biomarker World Congress

The data refer to persons aged between 15 and 54.

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

Clinical Study Synopsis

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

Rate Lock Policy. Contents

Fee Schedule - Home Health Care- 2015

Annex III. Amendments to relevant sections of the Product Information

New Guidance & Technical Specifications. Dr Ute Ströher, Technical Officer, IVD Assessment

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Measures to Minimize Influenza Transmission at Swine Exhibitions

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training

Reference: Patient A. Brenda WXXXXX Date of Birth: 4/15/57

* CORRESPO~~ING AUTHOR. YAWS/PMVH/jtf-88 IN CENTRAL AFRICA IMMUNOFLUORESCENCE FOR DIAGNOSIS GONZALEZ. MARTIN. M.H. GEORGES-COURBOT M.C. PALISSON. M.J.

Novel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

Study Design Open, three arm-stratified, non-randomized, prospective, multicentric study

Obesity/Morbid Obesity/BMI

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.

STANDARD OPERATING PROCEDURES (SOP) EXPANDING THE CONTINUUM OF CARE SATELLITE SITES

Solid Organ Transplant Benefits to Change for Texas Medicaid

CDC Influenza Technical Key Points February 15, 2018

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT

Policy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning

iprex Fact Sheet: Key Results

Childhood Immunization Status (NQF 0038)

Daily Balancing in Maestro

Safety of HPV vaccination: A FIGO STATEMENT

ITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.

2018 CMS Web Interface

2017 CMS Web Interface

Section 5. Study Procedures

April 23, 2008 Information Sheet: Safety of BPA-derived Can Liners. Summary

Code of employment practice on infant feeding

Summary Report: What Clinical Laboratories Need to Know About Their Role in Influenza Testing*

FDA Dietary Supplement cgmp

Continuous or Intermittent Monitoring of Glucose in Interstitial Fluid

Related Policies None

TOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH

H1N1 Influenza 09 Guidance for Residential Aged Care

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.

CDC Influenza Division Key Points MMWR Updates February 20, 2014

Cardiac Rehabilitation Services

Chronic Fatigue Syndrome

Diabetes: HbA1c Poor Control (NQF 0059)

Screening Test. Introduction:

Clinical Policy Title: Seasonal influenza testing

Clinical Quality Indicators

Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

Directorate of Laboratory Medicine

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

Action plan: serialisation of Nordic packages focus on Product Codes

Transcription:

HIV Diagnstic Tests HIV Testing Algrithm at SydPath (Natinal Reference Labratry) HIV1/2 Ab/Ag Cmbi is Architect HIV- 1 Ab/Ag EIA is Genscreen Sandwich EIA 4 th Generatin HIV Ab/Ag Chemiluminescene Micr particle Immunassay (CMIA; Architect) Magnetic micrparticles are bund t p24 Ag AND antibdies t HIV- 1 gp41 AND HIV- 2 gp36ab Incubated with patient sera t allw anti- p24 r HIV1/2 specific Ab t bind Wash steps are aided by the use f magnetic beads which retain ant Ag- Ab cmplexes A secndary Anti human Ab/recmbinant p24 is labelled with an enzyme e.g. HRP Additin f substrate e.g. TMB allws fr develpment f chemiluminescent prduct Readut is Optical density Psitive result is OD>1.0 Results may range int the 100s Nte the higher the OD readut the mre likely the result will be a true- psitive OD> 50 has PPV 99% and Sens 81% OD>151 has PPV 100% and Sens 68% S.Sassn 2016 1

Prs: High Sensitivity>99% Fully autmated Fast Cns: Specificity 98% Can have false psitives with interfering Ab Windw perid 2 weeks HIV Ab/Ag ELISA (e.g. Genscreen, Liasn) Sandwich ELISA detecting p24 Ag AND Antibdies t HIV- 1 (but NOT HIV- 2). Usually run n samples that have POSITIVE results n the Architect CMIA (x2) High Sensitivity; Lwer Specificity P24 ELISA The HIV p24 Ag frms part f the viral capsid Levels f Serum p24 are very high in HIV Sercnversin/Primary infectin prir t the frmatin f anti p24 Ab Patient will usually have detectable p24 until the develpment f anti p24 Ab n the HIV WB Measurement f p24 is used as an adjunct test in sme patients where: HIV1/2/Ag/Ab screen and EIA are POSITIVE HIV Western Blt is NEGATIVE r INDETERMINANT These cases may represent early infectin/sercnversin Detectin f p24 prvides additinal evidence f early HIV infectin The HIV p24 ELISA is a Capture ELISA Plate cated with anti p24 Ab Incubated with patient sera t allw free p24 t bind Fllwing wash incubated with antip24 secndary Ab HRP S.Sassn 2016 2

Fllwing washing additin f chemiluminescence substrate e.g. TMB and measurement via ptical density Nte that fr samples that have a POSITIVE initial p24 ELISA result a neutralisatin step is perfrmed. This is because the p24 ELISAs are subject t high rates f FALSE POSITIVES due t interfering substances and/r Ab cmplexes. In the neutralisatin assay patient sera is pre- incubated with an unlabelled anti p24 Ab prir t perfrming the ELISA. This means any p24 Ag will be bund in Ab- Ag cmplexes and therefre unable t be measured by the sandwich ELISA. A reductin in the OD f 50% is cnsidered evidence f neutralisatin and therefre cnfirms anti- p24 specificity. HIV Western Blt Detects Ab t HIV- 1 (HIV- 2 n separate blt) Prs: Very high Specificity Cns: Expensive May miss HIV sercnversin, Requires peratr interpretatin/ nn autmated readut Slwer TAT S.Sassn 2016 3

Classificatin f Indeterminant HIV Western Blts Grup Descriptin Interpretatin Specificity Reprting 1 Reactivity t viral bands but nt t p18, p24 r any gp bands Nn specific reactivity Lw specificity fr HIV infectin Nt reprted at SydPath 2 Reactivity t viral bands including p18 but nt t p24 r any gp prteins 3 Reactivity viral bands including t p24 but nt t gp prteins 4 Reactivity t viral prteins including gp prteins but with <3 ther viral prteins P18 plus nn- specific reactivity Cnsistent with early infectin Cnsistent with late stage infectin Lw specificity fr HIV infectin Higher specificity fr HIV infectin Higher specificity fr HIV infectin Nt reprted at SydPath Reprted at SydPath with cmment abut acute/early infectin Reprted at SydPath HIV Prviral DNA Assay Detects integrated and unintegrated HIV DNA Prs: Cns: S.Sassn 2016 Very high specificity Used as gld standard fr HIV infectin Helpful in HIV diagnsis in HIV sercnversin/early infectin when HIV Ag/Ab tests are psitive, p24 ELISA is psitive but HIV Western Blt is blank. Helpful in excluding vertical transmissin in children brn t HIV+ mthers; where HIV Western Blts may appear psitive due t transplacental crssing f Anti- HIV Ab. Quantitative readut nly Nn FDA apprved Only available in 1 lab in Australia (SydPath) 4

HIV Viral Lad (Cbas Taqman Amplicr) There are numerus cmmercial kits fr measurement f HIV viral lad which are based n quantitative PCR methds e.g. Rche Amplicr, Abbtt Real- time HIV- 1 test and Rche Cbas Taqman HIV- 1 test (used at SydPath) The Rche COBAS Taqman test uses FRET t enhance RT- PCR and specificity The PCR reactin relies n DNA template, primers and nucletides but als the additin f a Taqman Prbe that cnsist f a 5 flurchrme and 3 quench which quenches the flurescence when in clse prximity. The Taqman prbe binds t the target sequence f the DNA. As the Taq plymerase extends the primer during each rund f DNA amplificatin it degrades the prbe releasing the flurchrme. Therefre the amunt f detected Flurescent is directly prprtinal t the munt f template DNA. S.Sassn 2016 5

Past exam questins A patient with agammaglbulinaemia, n replacement intravenus immunglbulin therapy, requests an HIV test. Discuss the investigatin f HIV infectin in such a patient. (2013) As many HIV diagnstic tests are based n detectin f HIV- specific Ab in the patient, treatment with IVIG may interfere with diagnstic assays and indeed result in false negative results. The initial screening tests can still be perfrmed given bth 4 th generatin CMIA and EIA are based n detectin f bth HIV1/2 Ab AND Antigen and HIV- 1 Ab/Ag, respectively. A Psitive result wuld be cnsistent with HIV infectin but OD results may be lwer than expected due t the lack f patient- generated Ab. Therefre negative results need t be interpreted with cautin. The cnfirmatry test is mre difficult as the HIV western blt is based n detectin f anti- HIV Ab. Given the patient is stated as having Agammaglbulinemia (as ppsed t hypgammaglbulinemia) there is prbably little advantage in running an HIV WB as the nly Ab detected will be frm pled dnrs Instead the HIV Prviral DNA test shuld be perfrmed as the cnfirmatry test in this patient While nt FDA apprved this test is being perfrmed at a Natinal reference labratry in Australia under a special license. HIV viral lad testing e.g. Rche COBAS Taqman test is NOT licenced as an HIV diagnstic test, hwever may be used as an adjunctive test r subsequent mnitring test if abve HIV Ag/Ab screen and prviral DNA testing is psitive. The HIV Viral lad and CD4 cunt will nt be affected by agammaglbulinemia. Outline a prtcl fr the (pst- partum) assessment f pssible transmissin f HIV- 1 infectin t the child f a HIV- 1 infected wman. (2011) The fllwing tests shuld be perfrmed at Birth, 6 weeks, 3 mnths (6 and 12 mnths ptinal) and 18 mnths HIV western blt We wuld expect WB t be cmplete/mature given transplacental crss f maternal anti- HIV Ab Overtime shuld see de- evlutin f HIV WB in infant wh is uninfected HIV prviral DNA A negative result demnstrated infant in uninfected S.Sassn 2016 6

ASID Guidelines: *Nte: ASID Guidelines differ frm standard clinical practice at SydPath where HIV WB and Prviral DNA measurement are run in parallel. S.Sassn 2016 7

List the assays that are useful in the evaluatin f patients with suspected HIV sercnversin illness (primary HIV infectin) and their respective limitatins. (2012, 2010) Test Prs Cns 4 th Generatin CMIA HIV1/2 Ab/Ag test Fast TAT On demand testing Very high sensitivity?99% and Specificity >98% Detects Ab t HIV1 and HIV2 Quantitative 4 th Generatin EIA fr HIV Ab/Ag Fast Cheap Easy t run Quantitative P24 ELISA Detectin f free p24 in patients with psitive Ab/Ag screen but negative/indeterminant western blt Cheap Easy t run Quantitative 2 week windw perid Requires expensive instrumentatin Des nt detect HIV- 2 2-6 week windw perid High rates f false psitives Requires extra pre- treatment with nab if psitive t determine P24 specificity Slwer TAT HIV Western Blt Very high specificity >99% Separate blt available fr HIV- 2 Prviral DNA Used as reference standard fr HIV infectin Can be used t determine vertical transmissin in infants brn t HIV+ mthers Expensive Usually batched- s lnger TAT Nt fully autmatable Requires peratr interpretatin Nn quantitative/qualitative Can have indeterminant results Nn FDA apprved Only run at Natinal Reference Labratry under special licence Slwer TAT S.Sassn 2016 8